193 related articles for article (PubMed ID: 23160320)
21. Crizotinib: a new treatment option for ALK-positive non-small cell lung cancer.
O'Bryant CL; Wenger SD; Kim M; Thompson LA
Ann Pharmacother; 2013 Feb; 47(2):189-97. PubMed ID: 23386065
[TBL] [Abstract][Full Text] [Related]
22. Summary of presentation from the targeted therapy in lung cancer meeting.
Govindan R
J Thorac Oncol; 2011 Nov; 6(11 Suppl 4):S1757. PubMed ID: 22005528
[TBL] [Abstract][Full Text] [Related]
23. The articles in this supplement should be viewed more as meeting reports than as exhaustive and comprehensive review articles. Introduction.
Govindan R
J Thorac Oncol; 2012 Dec; 7(16 Suppl 5):S341. PubMed ID: 23160319
[No Abstract] [Full Text] [Related]
24. [Personalized treatment in non-small cell lung cancer].
Campos-Parra AD; Cruz-Rico G; Arrieta O
Rev Invest Clin; 2012; 64(4):377-86. PubMed ID: 23227588
[No Abstract] [Full Text] [Related]
25. Targeting vascular endothelial growth factor in lung cancer.
Hasani A; Leighl NB
J Thorac Oncol; 2010 Dec; 5(12 Suppl 6):S484-6. PubMed ID: 21102250
[No Abstract] [Full Text] [Related]
26. Targeting MEK for the treatment of non-small-cell lung cancer.
Goldman JW; Garon EB
J Thorac Oncol; 2012 Dec; 7(16 Suppl 5):S377-8. PubMed ID: 23160324
[No Abstract] [Full Text] [Related]
27. Emerging gene mutation targets in lung cancer.
Johnson BE
Clin Adv Hematol Oncol; 2015 Dec; 13(12):812-4. PubMed ID: 27058846
[No Abstract] [Full Text] [Related]
28. Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer.
Fumarola C; Bonelli MA; Petronini PG; Alfieri RR
Biochem Pharmacol; 2014 Aug; 90(3):197-207. PubMed ID: 24863259
[TBL] [Abstract][Full Text] [Related]
29. Targeting the phosphatidylinosital 3-kinase, Akt, and mammalian target of rapamycin pathway in non-small cell lung cancer.
Cuffe S; Leighl NB
J Thorac Oncol; 2011 Nov; 6(11 Suppl 4):S1805-7. PubMed ID: 22005538
[No Abstract] [Full Text] [Related]
30. Insulin-like growth factor receptor.
Blumenschein G
J Thorac Oncol; 2011 Nov; 6(11 Suppl 4):S1799-800. PubMed ID: 22005535
[No Abstract] [Full Text] [Related]
31. More Benefits for Checkpoint Inhibitors in NSCLC.
Cancer Discov; 2015 Dec; 5(12):OF2. PubMed ID: 26511141
[TBL] [Abstract][Full Text] [Related]
32. Targeted therapy of non-small-cell lung carcinoma.
Tiwari D; Brodie SA; Brandes JC
Ther Adv Respir Dis; 2012 Feb; 6(1):41-56. PubMed ID: 21730004
[TBL] [Abstract][Full Text] [Related]
33. Epidermal growth factor receptor pathway.
Bonomi P
J Thorac Oncol; 2010 Dec; 5(12 Suppl 6):S470-1. PubMed ID: 21102243
[No Abstract] [Full Text] [Related]
34. Novel mechanisms and targets: miscellaneous agents.
Reckamp KL
J Thorac Oncol; 2011 Nov; 6(11 Suppl 4):S1812-4. PubMed ID: 22005541
[No Abstract] [Full Text] [Related]
35. [Cyclooxygenase 2 inhibitors and lung carcinoma].
Spano JP; Chouahnia K; Morère JF
Bull Cancer; 2004 May; 91 Spec No():S109-12. PubMed ID: 15239338
[TBL] [Abstract][Full Text] [Related]
36. New treatment strategies in patients with advanced non-small-cell lung cancer and performance status 2.
Rodriguez E; Lilenbaum RC
Clin Lung Cancer; 2008 Nov; 9(6):326-30. PubMed ID: 19073514
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of MET receptor tyrosine kinase and its ligand hepatocyte growth factor.
Sadiq AA; Geynisman DM; Salgia R
J Thorac Oncol; 2011 Nov; 6(11 Suppl 4):S1810-1. PubMed ID: 22005540
[No Abstract] [Full Text] [Related]
38. Toward customized trastuzumab in HER-2/neu-overexpressing non-small-cell lung cancers.
Rosell R
J Clin Oncol; 2004 Apr; 22(7):1171-3. PubMed ID: 14981109
[No Abstract] [Full Text] [Related]
39. EML4/ALK and ras inhibitors.
Edelman MJ
J Thorac Oncol; 2010 Dec; 5(12 Suppl 6):S495-6. PubMed ID: 21102254
[No Abstract] [Full Text] [Related]
40. The role of targeting mammalian target of rapamycin in lung cancer.
Pal SK; Figlin RA; Reckamp KL
Clin Lung Cancer; 2008 Nov; 9(6):340-5. PubMed ID: 19073516
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
